Advanced

Cost effectiveness of nasal budesonide versus surgical treatment for nasal polyps

Berggren, Fredrik LU and Johansson, L (2003) In PharmacoEconomics 21(5). p.351-356
Abstract
Objective: To conduct a cost-effectiveness study of nasal budesonide versus surgical treatment in the management of nasal polyps. Design and methods: A decision-tree model reflecting two different treatment strategies for nasal polyps in Sweden was developed. The first strategy was initial polypectomy, performed under three different sets of circumstances: inpatient functional endoscopic surgery, outpatient evulsion with sedation, or outpatient evulsion with local anaesthesia; all treatments were followed by intranasal treatment with budesonide (Rhinocort(R)) 128mug twice daily. The second strategy was initial intranasal treatment with budesonide 128mug twice daily. Perspective: Healthcare provider perspective. Outcome measures and... (More)
Objective: To conduct a cost-effectiveness study of nasal budesonide versus surgical treatment in the management of nasal polyps. Design and methods: A decision-tree model reflecting two different treatment strategies for nasal polyps in Sweden was developed. The first strategy was initial polypectomy, performed under three different sets of circumstances: inpatient functional endoscopic surgery, outpatient evulsion with sedation, or outpatient evulsion with local anaesthesia; all treatments were followed by intranasal treatment with budesonide (Rhinocort(R)) 128mug twice daily. The second strategy was initial intranasal treatment with budesonide 128mug twice daily. Perspective: Healthcare provider perspective. Outcome measures and results: After 1 month, treatment with nasal budesonide was classified as a success (82.5%) or a failure (17.5%) based on clinical study data. In cases of success, the treatment was continued, and in cases of failure, polypectomy was undertaken, followed by budesonide 128mug twice daily. Treatments were evaluated after 4 months using prices from the Central Hospital in Skovde, Sweden. The expected reduction in cost from using initial nasal budesonide treatment compared with the different alternatives of polypectomy were 9760 Swedish kronors (SEK) for inpatient functional endoscopic surgery, SEK2747 for outpatient evulsion with sedation, and SEK672 for outpatient evulsion with anaesthesia (1998 values). Nasal budesonide 128 mug twice daily treatment for nasal polyps revealed a potential reduction in costs of 53% compared with the primary surgery approach. Conclusion: Initial treatment of nasal polyps with nasal budesonide provides lower costs than treatment with initial polypectomy with maintained effectiveness. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
PharmacoEconomics
volume
21
issue
5
pages
351 - 356
publisher
Adis International
external identifiers
  • wos:000182092500006
  • pmid:12627988
  • scopus:0037248027
ISSN
1179-2027
language
English
LU publication?
yes
id
4d6d7711-51e7-4592-9e2d-f28a723d21d7 (old id 313274)
alternative location
http://www.ingentaconnect.com/content/adis/pec/2003/00000021/00000005/art00006
date added to LUP
2007-08-23 08:19:39
date last changed
2018-01-07 09:20:56
@article{4d6d7711-51e7-4592-9e2d-f28a723d21d7,
  abstract     = {Objective: To conduct a cost-effectiveness study of nasal budesonide versus surgical treatment in the management of nasal polyps. Design and methods: A decision-tree model reflecting two different treatment strategies for nasal polyps in Sweden was developed. The first strategy was initial polypectomy, performed under three different sets of circumstances: inpatient functional endoscopic surgery, outpatient evulsion with sedation, or outpatient evulsion with local anaesthesia; all treatments were followed by intranasal treatment with budesonide (Rhinocort(R)) 128mug twice daily. The second strategy was initial intranasal treatment with budesonide 128mug twice daily. Perspective: Healthcare provider perspective. Outcome measures and results: After 1 month, treatment with nasal budesonide was classified as a success (82.5%) or a failure (17.5%) based on clinical study data. In cases of success, the treatment was continued, and in cases of failure, polypectomy was undertaken, followed by budesonide 128mug twice daily. Treatments were evaluated after 4 months using prices from the Central Hospital in Skovde, Sweden. The expected reduction in cost from using initial nasal budesonide treatment compared with the different alternatives of polypectomy were 9760 Swedish kronors (SEK) for inpatient functional endoscopic surgery, SEK2747 for outpatient evulsion with sedation, and SEK672 for outpatient evulsion with anaesthesia (1998 values). Nasal budesonide 128 mug twice daily treatment for nasal polyps revealed a potential reduction in costs of 53% compared with the primary surgery approach. Conclusion: Initial treatment of nasal polyps with nasal budesonide provides lower costs than treatment with initial polypectomy with maintained effectiveness.},
  author       = {Berggren, Fredrik and Johansson, L},
  issn         = {1179-2027},
  language     = {eng},
  number       = {5},
  pages        = {351--356},
  publisher    = {Adis International},
  series       = {PharmacoEconomics},
  title        = {Cost effectiveness of nasal budesonide versus surgical treatment for nasal polyps},
  volume       = {21},
  year         = {2003},
}